Abbott study links Cologuard screening to 54% lower colorectal cancer incidence
ABT•Abbott said a real-world study linked completing its Cologuard stool DNA screening test to 54% lower colorectal cancer incidence than non-completion among average-risk adults. A separate analysis associated prior screening completion with lower odds of death after a colorectal cancer diagnosis.
1. Study findings
Abbott flagged real-world studies of its Cologuard stool DNA screening test, with results presented at ACG 2026. One study linked test completion to fewer colorectal cancer diagnoses than non-completion in a nationwide cohort of average-risk adults; a separate case-control analysis associated prior screening completion with lower odds of death following a colorectal cancer diagnosis.
